The need for a rapid onset of action and a long duration of the broncholytic effect is the likely reason for the development of new long-acting β2-agonists (LABAs) that are fast acting and have true 24 h duration of action. Indacaterol is the archetype of once-daily LABAs and already marketed as a maintenance therapy in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Matera, M., Rogliani, P., Cazzola, M. (2015). Indacaterol for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 16(1), 107-115 [10.1517/14656566.2015.983076].
Indacaterol for the treatment of chronic obstructive pulmonary disease
ROGLIANI, PAOLA;CAZZOLA, MARIO
2015-01-01
Abstract
The need for a rapid onset of action and a long duration of the broncholytic effect is the likely reason for the development of new long-acting β2-agonists (LABAs) that are fast acting and have true 24 h duration of action. Indacaterol is the archetype of once-daily LABAs and already marketed as a maintenance therapy in patients with moderate to severe chronic obstructive pulmonary disease (COPD).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
